Claire T Deakin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5767165/publications.pdf

Version: 2024-02-01

24 papers	1,725 citations	687220 13 h-index	642610 23 g-index
24 all docs	24 docs citations	24 times ranked	4002 citing authors

#	Article	IF	Citations
1	Association with HLA-DRÎ²1 position 37 distinguishes juvenile dermatomyositis from adult-onset myositis. Human Molecular Genetics, 2022, 31, 2471-2481.	1.4	9
2	Identification and prediction of novel classes of long-term disease trajectories for patients with juvenile dermatomyositis using growth mixture models. Rheumatology, 2021, 60, 1891-1901.	0.9	6
3	Use of Rescue Therapy with IVIG or Cyclophosphamide in Juvenile Myositis. Current Rheumatology Reports, 2021, 23, 24.	2.1	1
4	Favorable antibody responses to human coronaviruses in children and adolescents with autoimmune rheumatic diseases. Med, 2021, 2, 1093-1109.e6.	2.2	6
5	JAK inhibitors: a potential treatment for JDM in the context of the role of interferon-driven pathology. Pediatric Rheumatology, 2021, 19, 146.	0.9	19
6	A survey to understand the feelings towards and impact of COVID-19 on the households of juvenile dermato myositis patients from a parent or carer perspective. Rheumatology Advances in Practice, 2021, 5, rkab058.	0.3	3
7	Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nature Communications, 2020, 11, 6317.	5.8	1,042
8	Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients. Arthritis Research and Therapy, 2020, 22, 79.	1.6	30
9	Expression of myxovirusâ€resistance protein A: a possible marker of muscle disease activity and autoantibody specificities in juvenile dermatomyositis. Neuropathology and Applied Neurobiology, 2019, 45, 410-420.	1.8	36
10	Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. Annals of the Rheumatic Diseases, 2019, 78, 996-1002.	0.5	81
11	Galectinâ€9 and CXCL10 as Biomarkers for Disease Activity in Juvenile Dermatomyositis: A Longitudinal Cohort Study and Multicohort Validation. Arthritis and Rheumatology, 2019, 71, 1377-1390.	2.9	51
12	Modelling disease activity in juvenile dermatomyositis: A Bayesian approach. Statistical Methods in Medical Research, 2019, 28, 35-49.	0.7	6
13	Efficacy and Safety of Cyclophosphamide Treatment in Severe Juvenile Dermatomyositis Shown by Marginal Structural Modeling. Arthritis and Rheumatology, 2018, 70, 785-793.	2.9	41
14	Systemic and Tissue Inflammation in Juvenile Dermatomyositis: From Pathogenesis to the Quest for Monitoring Tools. Frontiers in Immunology, 2018, 9, 2951.	2.2	50
15	CD19+CD24hiCD38hi B Cells Are Expanded in Juvenile Dermatomyositis and Exhibit a Pro-Inflammatory Phenotype After Activation Through Toll-Like Receptor 7 and Interferon-Î±. Frontiers in Immunology, 2018, 9, 1372.	2.2	68
16	Clinical signs and symptoms in a joint model of four disease activity parameters in juvenile dermatomyositis: a prospective, longitudinal, multicenter cohort study. Arthritis Research and Therapy, 2018, 20, 180.	1.6	8
17	Sex and Pubertal Differences in the Type 1 Interferon Pathway Associate With Both X Chromosome Number and Serum Sex Hormone Concentration. Frontiers in Immunology, 2018, 9, 3167.	2.2	87
18	Muscle Biopsy Findings in Combination With Myositisâ€Specific Autoantibodies Aid Prediction of Outcomes in Juvenile Dermatomyositis. Arthritis and Rheumatology, 2016, 68, 2806-2816.	2.9	83

#	Article	IF	Citations
19	O44.â€ƒAn Integrative Analytical Approach to Subphenotyping of Juvenile Dermatomyositis. Rheumatology, 2015, , .	0.9	0
20	Impact of next-generation sequencing error on analysis of barcoded plasmid libraries of known complexity and sequence. Nucleic Acids Research, 2014, 42, e129-e129.	6.5	31
21	Gene Therapy Researchers' Assessments Of Risks And Perceptions Of Risk Acceptability In Clinical Trials. Molecular Therapy, 2013, 21, 806-815.	3.7	10
22	The ethics of gene therapy: balancing the risks. Current Opinion in Molecular Therapeutics, 2010, 12, 578-85.	2.8	7
23	Accepting Risk in Clinical Research: Is the Gene Therapy Field Becoming Too Risk-averse?. Molecular Therapy, 2009, 17, 1842-1848.	3.7	37
24	Limiting Î³c expression differentially affects signaling via the interleukin (IL)-7 and IL-15 receptors. Blood, 2007, 110, 91-98.	0.6	13